Home > Our expertise > Our experts > Senior Researchers > Dr Robert Weinkove

Dr Robert Weinkove

Clinical Director, CAR T-cell Clinical Programme Leader

Dr Robert Weinkove is  the Wade Thompson Clinical Research Fellow and Clinical Director at the Malaghan Institute of Medical Research. His is also in clinical practice as a Consultant Haematologist at Wellington Blood & Cancer Centre, Capital and Coast District Health Board. 

Dr Weinkove's clinical and research interests are B-cell malignancies, cancer immunotherapy and haemato-oncology supportive care. He studied medicine at the University of Cambridge and Kings College London, trained in General Medicine and Haematology at Guy's and St Thomas' Hospitals in London and the Medizinische Hochschule Hannover in Germany, and completed an Immunology PhD with the University of Otago. Dr Weinkove is developing a clinical CAR-T cell programme in conjunction with Wellington Zhaotai Therapies Ltd.

MA (Cantab), MBBS (Hons), PhD, FRACP, FRCP

Publications

2021

Nouri Y, Weinkove R, Perret R (2021). T-cell intrinsic Toll-like receptor signaling: implications for cancer immunotherapy and CAR T-cells. J Immunother Cancer. 9(11):e003065

Jarvis E-M, Collings S, Authier-Hall A, Dasyam N, Luey B, Nacey J, Painter GF, Delahunt B, Hermans IF and Weinkove R (2021). Mucosal-Associated Invariant T (MAIT) Cell Dysfunction and PD-1 Expression in Prostate Cancer: Implications for Immunotherapy. Front. Immunol. 12:748741

Cochrane T, Enrico A, Gomez-Almaguer D, Hadjiev E, Lech-Maranda E, Masszi T, Nikitin E, Robak T, Weinkove R, Wu SJ, Sail KR, Pesko J, Pai M, Komlosi V, Anderson MA (2021). Impact of venetoclax monotherapy on the quality of life of patients with relapsed or refractory chronic lymphocytic leukemia: results from the phase 3b VENICE II trial. Leuk Lymphoma. 1-11

Weinkove R, George P, Ruka M, Haira TH, Giunti G (2021). Chimeric antigen receptor T-cells in New Zealand: challenges and opportunities. N Z Med J. 134(1542):96-108

2020

Di Ciaccio P, McCaughan G, Trotman J, Ho PJ, Cheah CY, Gangatharan S, Wight J, Ku M, Quach H, Gasiorowski R, Polizzotto MN, Prince HM, Mulligan S, Tam CS, Gregory G, Hapgood G, Spencer A, Dickinson M, Latimer M, Johnston A, Armytage T, Lee C, Cochrane T, Berkhahn L, Weinkove R, Doocey R, Harrison SJ, Webber N, Lee HP, Chapman S, Campbell BA, Gibbs SDJ, Hamad N (2020). Australian and New Zealand consensus statement on the management of lymphoma, chronic lymphocytic leukaemia and myeloma during the COVID-19 pandemic. Intern Med J.

Weinkove R, McQuilten ZK, Adler J, Agar MR, Blyth E, Cheng AC, Conyers R, Haeusler GM, Hardie C, Jackson C, Lane SW, Middlemiss T, Mollee P, Mulligan SP, Ritchie D, Ruka M, Solomon B, Szer J, Thursky KA, Wood EM, Worth LJ, Yong MK, Slavin MA, Teh BW (2020). Managing haematology and oncology patients during the COVID-19 pandemic: interim consensus guidance. Med J Aust. 2020

George P, Brown A, Weinkove R (2020). B-cell Prolymphocytic Leukaemia With a t(4;14) FGFR3/IGH Translocation: Response to Ibrutinib. Pathology. 52(4):491-492.

Grasso C, Field CS, Tang CW, Ferguson PM, J Compton B, Anderson RJ, Painter GF, Weinkove R, F Hermans I, Berridge MV (2020). Vaccines adjuvanted with an NKT cell agonist induce effective T-cell responses in models of CNS lymphoma. Immunotherapy.

Dasyam N, George P, Weinkove R (2020). Chimeric antigen receptor T-cell therapies: Optimising the dose. Br J Clin Pharmacol.

George P, Dasyam N, Giunti G, Mester B, Bauer E, Andrews B, Perera T, Ostapowicz T, Frampton C, Li P, Ritchie D, Bollard CM, Hermans IF, Weinkove R (2020). Third-generation anti-CD19 chimeric antigen receptor T-cells incorporating a TLR2 domain for relapsed or refractory B-cell lymphoma: a phase I clinical trial protocol (ENABLE). BMJ Open.10(2):e034629 

Stanworth SJ, Killick S, McQuilten ZK, Karakantza M, Weinkove R, Smethurst H, Pankhurst LA, Hodge RL, Hopkins V, Thomas HL, Deary AJ, Callum J, Lin Y, Wood EM, Buckstein R, Bowen D; REDDS Investigators (2020). Red cell transfusion in outpatients with myelodysplastic syndromes: a feasibility and exploratory randomised trial. Br J Haematol. 189(2):279-290 

2019

Weng J, Lai P, Qin L, Lai Y, Jiang Z, Luo C, Huang X, Wu S, Shao D, Deng C, Huang L, Lu Z, Zhou M, Zeng L, Chen D, Wang Y, Chen X, Geng S, Weinkove R, Tang Z, He C, Li P, Du X (2019). Correction to: A novel generation 1928zT2 CAR T cells induce remission in extramedullary relapse of acute lymphoblastic leukemia. J Hematol Oncol. 12(1):117 

Dickinson M, Weinkove R (2019). Maintaining a fit T-cell compartment: lymphoma treatment sequencing in the era of chimeric antigen receptor T-cell therapies. Intern Med J. 49(10):1338 

Compton BJ, Farrand KJ, Tang CW, Osmond TL, Speir M, Authier-Hall A, Wang J, Ferguson PM, Chan STS, Anderson RJ, Cooney TR, Hayman CM, Williams GM, Brimble MA, Brooks CR, Yong LK, Metelitsa LS, Zajonc DM, Godfrey DI, Gasser O, Weinkove R, Painter GF, Hermans IF (2019) Enhancing T cell responses and tumour immunity by vaccination with peptides conjugated to a weak NKT cell agonist. Org & Biomol Chem 17(5):1225-1237

Wong J, Wood EM, Crispin P, Weinkove R, McQuilten ZK; Australasian Leukaemia and Lymphoma Group (ALLG) Supportive Care Group (2019) Managing hypogammaglobulinaemia secondary to haematological malignancies in Australia and New Zealand: a clinician survey. Intern Med J49(3):358-363

Fischer K, Al-Sawaf O, Bahlo J, Fink AM, Tandon M, Dixon M, Robrecht S, Warburton S, Humphrey K, Samoylova O, Liberati AM, Pinilla-Ibarz J, Opat S, Sivcheva L, Le Dû K, Fogliatto LM, Niemann CU, Weinkove R, Robinson S, Kipps TJ, Boettcher S, Tausch E, Humerickhouse R, Eichhorst B, Wendtner CM, Langerak AW, Kreuzer KA, Ritgen M, Goede V, Stilgenbauer S, Mobasher M, Hallek M (2019) Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions. N Engl J Med 380(23):2225-2236

Weinkove R, George P, Dasyam N, McLellan AD (2019) Selecting costimulatory domains for chimeric antigen receptors: functional and clinical considerations. Clin Transl Immunology 8(5):e1049

Weinkove R, Bowden E, Wood C, Campion V, Carter J, Hall R, Weatherall M, Beasley R, Young P (2019) A randomized controlled feasibility trial of paracetamol during febrile neutropenia in hemato-oncology patients. Leukemia & Lymphoma 1-8 60(6):1540-1547

2018

Wheeler M, White G, Brockie S, Dickson M, Weinkove R (2018) Flow Cytometric Analysis of Mechanically Disaggregated Bone Marrow Trephine Biopsies. Cytometry B Clin Cytom94(6):935-940

Weng J, Peilong L, Le Q, Yunxin L, Zhiwu J, Chenwei L, Xin H, Suijin W, Shao D, Chengxin D, Lisi H, Zesheng L,  Maohua Z, Lingji Z, Dongmei C, Yulian W, Xiaomei C, Suxia G, Weinkove R, Zhaoyang T, Chang H,  Peng L, Xin D (2018) A novel generation 1928zT2 CAR T cells induce remission in extramedullary relapse of acute lymphoblastic leukemia. J Hemat Oncol 11(1):25

Gasser O, Sharples KJ, barrow C, Williams GM, Bauer E, Wood CE, Mester B, Dzhelali M, Caygill G, Jones J, Haman CM, Hinder VA, Macapagal J, McCuster M, Weinkove R, Painter GF, Brimble MA, Findlay MP, Dunbar PR, Hermans IF (2018) A phase I vaccination study with dendritic cells loaded with NY-ESO-1 & a-galactosylceramide: induction of polyfunctional T cells in high risk melanoma patients.Cancer Immunol Immunother 67(2):285-298

2017

Speir M, Authier-Hall A, Brooks CR, Farrand KJ, Compton BJ, Anderson RJ, Heiser A, Osmond TL, Tang CW, Berzofsky JA, Terabe M, Painter GF, Hermans IF, Weinkove R (2017) Glycolipid-peptide conjugate vaccines enhance CD8+ T cell responses against human viral proteins. Scientific Reports7:14273

Lucas N, Humble M, Sim D, Balm M, Carter JM and Weinkove R (2017) Temporal changes in neutropenic blood culture isolates: and disease associations: a single centre series of 1139 episodes. Int Med J 47(8):962-965

Speir, M., Hermans, I.F. and Weinkove, R. (2017) Engaging natural killer T cells as 'universal helpers' for vaccination. Drugs 

2016

Collings S, Thompson O, Hirst E, Goossens L, George A, Weinkove R  (2016) Non-Invasive Detection of Anaemia Using Digital Photographs of the Conjunctiva. PLoS One